The global amylase testing market was valued at around US$ 587.1 Million at the end of 2021. The market is projected to register a 3.1% CAGR and top a valuation of US$ 830.2 Million by 2032.
Amylase testing demand is being driven by an increase in pancreatic diseases such as acute pancreatitis, alcohol related pancreatitis, cholecystitis, and others in the general population.
The amylase test, also known as the "amy test," "serum amylase," or "urine amylase test," is a diagnostic procedure used to assess the amount of amylase in the blood and urine. Our body naturally produces amylase, an enzyme that facilitates the breakdown of complex carbohydrates like starch. Our salivary glands and pancreas are where most of our amylase is found as "salivary amylase" and "pancreatic amylase," respectively.
An amylase test is mostly used to evaluate pancreatic health. Amylase levels that are abnormal in the blood and urine point to a problem with the pancreas or an infection. The test results can assist the doctor in diagnosing the problem and recommending additional care.
The blood's normal amylase level should range from 30 to 110 units per litre (U/L). The pancreas may be in risk if there is any variation from the normal range.
Tumours, gall bladder infections, and kidney failure can cause hyperamylasaemia.
| Attributes | Details |
| Amylase Testing Market Value in 2021 | US$ 587.1 Million |
| Amylase Testing Market Value in 2032 | US$ 830.2 Million |
| Amylase Testing Market CAGR (2022 to 2032) | 3.1% |
The market for amylase testing is anticipated to develop as a result of growing use of amylase testing for accurate assessment of pancreatic and salivary gland function.
The market is expanding due to the efficiency with which amylase testing is able to diagnose conditions like acute, chronic, or alcoholic pancreatitis, ruptured ectopic pregnancies, digestive problems (such perforated peptic ulcers, appendicitis, salivary gland infections, or tumours), and more.
Amylase testing market expansion is anticipated to be aided by the simplicity of using blood or urine samples for the test. Additionally, increasing chronic conditions such as pancreatitis which is more common in smokers is increasing day by day which is supposed to boost the market growth over the forecast period. For instance, according to BMC gastroenterology article published in August 2021, around 2,814,973 cases of acute pancreatitis worldwide were founded in 2019, in which the smoking was considered as the key risk factor.
Furthermore, the market for amylase testing is growing as a result of the chemicals and equipment needed for testing amylase being widely accessible.
Moreover, the market for amylase testing is driven due to the expansion of regional manufacturers, particularly in areas like East Asia, South Asia, and the GCC nations. These manufacturers make products that are more affordable and are therefore more readily available, which increases product adoption.
The amylase testing market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
North America dominated the regional amylase testing market in terms of revenue, due to greater product utilization in the region. Additionally, growing geriatric population with increasing prevalence of pancreatic cancer in them is supposed to drive the regional market. For instance, in 2022, according to American Cancer Society about 62,210 patients were diagnosed with pancreatic cancer, in which around 49,830 died due to it.
Additionally, it also states in U.S, the pancreatic cancer accounts for about 3% of all cancer and about 7% of death occurs due to pancreatic cancer.
Moreover, in Latin America the market is supposed to steadily increase over the coming years due to region's expanding product availability.
Moreover, Europe is anticipated to be the second most lucrative region due to the greater product acceptance in the region.
Amano Enzyme, Novozymes, DSM, BASF, Advanced Enzyme Tech., Suzhou Sino Enzymes, Shenzhen Leveking Bio-Engineering, Chemzyme Biotechnology, Enmex, and Biolaxi
| Report Attributes | Details |
| Growth Rate | CAGR of 3.1% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segment Covered |
|
| Region Covered |
|
| Key Countries Profiled |
|
| Key Players |
|
| Customization | Available Upon Request |
The global amylase testing market is anticipated to register a CAGR of 3.1% during the forecast period.
Amano Enzyme, Novozymes, DSM, BASF, Advanced Enzyme Tech., Suzhou Sino Enzymes, Shenzhen Leveking Bio-Engineering, Chemzyme Biotechnology, Enmex, and Biolaxi, among others are some prominent Amylase Testing Market players.
Explore Similar Insights
Amylase Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
